These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 22762454

  • 1. Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A.
    Klintman J, Hillarp A, Donfield S, Berntorp E, Astermark J.
    Haemophilia; 2013 Jan; 19(1):106-12. PubMed ID: 22762454
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM.
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [Abstract] [Full Text] [Related]

  • 7. A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients.
    Montalvão SA, Tucunduva AC, Siqueira LH, Sambo AL, Medina SS, Ozelo MC.
    Haemophilia; 2015 Sep; 21(5):686-92. PubMed ID: 25708525
    [Abstract] [Full Text] [Related]

  • 8. Factor VIII-specific B cell responses in haemophilia A patients with inhibitors.
    van Helden PM, Van Haren SD, Fijnvandraat K, van den Berg HM, Voorberg J.
    Haemophilia; 2010 May; 16(102):35-43. PubMed ID: 20536984
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
    Bacon CL, Singleton E, Brady B, White B, Nolan B, Gilmore RM, Ryan C, Keohane C, Jenkins PV, O'Donnell JS.
    Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
    Epstein J, Xiong Y, Woo P, Li-McLeod J, Spotts G.
    Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.